Current Issue

July 2025

Health Care Harmed

With President Trump’s cuts to research funding and restrictions on research initiatives, hematologists say the field will struggle to move forward.

Viewpoints

Editor’s Corner

Miles to Go Before We Sleep

Education

You Make the Call

You Make the Call: What testing and treatment would you recommend for two patients with elevated factor levels post-stroke?

You Make the Call: Reader's Response

What testing and treatment would you recommend for two patients with elevated factor levels post-stroke?

Spotlight

Feature Articles

Health Care Harmed

News

On Location

Five-Year Follow-Up Demonstrates Durable Responses to Cilta-Cel in R/R MM
Phase II Results Point Toward a New Era in Treating Acute Myeloid Leukemia
PVEK Shows Promising Efficacy in Blastic Plasmacytoid Dendritic Cell Neoplasm
MRD Negativity Associated With PFS and OS Benefit in DREAMM-8 Multiple Myeloma Trial
Results of Phase III Trial of Rusfertide Could Change Polycythemia Vera Treatment
Ibrutinib-Venetoclax Combination Shows High Rate of Response in Patients With Treatment-Naïve MCL
Subcutaneous Mosunetuzumab Could Be Administered in Community Setting to Patients With Follicular Lymphoma
Ropeg May Provide New Treatment Option for Essential Thrombocythemia
Trispecific Antibody Safe With High Efficacy in Phase I R/R MM Study
Small Activating RNA-Mediated Induction of HBG Gene Via In Vivo Delivery Shows Potential in SCD
Another Potential Product for Fibrinogen Concentrate for Congenital Fibrinogen Deficiency
Azacitidine Demonstrates Sustained Efficacy in VEXAS Syndrome
Iptacopan Increases Hemoglobin in Paroxysmal Nocturnal Hemoglobinuria

In a Different Vein: News from the Blood Journals

Use of Machine Learning Improves Outcome Predictions for Myelofibrosis After AlloHCT

Literature Scan

Iron Deficiency Potentially Underdiagnosed in Females With Bleeding Disorders

PDUFA Pending

Rilzabrutinib Offers Significant Advantages for Treatment of ITP

ASH Directions

ASH Commits More Than $12 Million to Address Challenges Facing the Field

Data Stream

July 2025 Data Stream

Online Only

On Location

Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL/SLL
Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib
Patients With R/R CLL/SLL Achieve Tumor Response With DZD8586
Results Detail Comparison of Patients With R/R CLL/SLL in Liso-Cel TRANSCEND CLL 004 Trial With Real-World SOC Cohort
Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo
R-Pola-Glo Shows High Response Rates in Unfit, Older Patients With DLBCL
Pneumococcal Meningitis Mortality Remains High in Children in France With SCD
Isatuximab-Based Quad Therapy Delivers Improved MRD Negativity in NDMM
Low Rates of High-Grade Toxicities Seen With Fresh CAR T-Cell Therapy in R/R NHL